Wagner, Gabor published the artcile4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as high-affinity non-imidazole histamine H3 receptor agonists with in vivo central nervous system activity, Product Details of C7H10ClN3, the main research area is aminoazetidinylpyrimidine amine preparation human histamine H3 receptor agonist.
Despite the high diversity of histamine H3 receptor (H3R) antagonist/inverse agonist structures, partial or full H3R agonists have typically been imidazole derivatives An inhouse screening campaign intriguingly afforded the non-imidazole 4-(3-azetidin-1-yl)pyrimidin-2-amine I (R1 = CHMe2, R2 = Me) (II) as partial H3R agonist. Here, the design, synthesis and structure-activity relationships of analogs of II are described. This series yields several non-imidazole full agonists with potencies varying with the alkyl substitution pattern on the basic amine following the in vitro evaluation of H3R agonism using a CRE-luciferase reporter gene assay. The key compound VUF16839, I (R1 = H, R2 = n-Pr) (III), combines nanomolar on-target activity (pKi = 8.5, pEC50 = 9.5) with weak activity on CYP enzymes and good metabolic stability. The proposed H3R binding mode of III indicates key interactions similar to those attained by histamine. In vivo evaluation of III in a social recognition test in mice, revealed an amnesic effect at 5 mg/kg i.p. The excellent in vitro and in vivo pharmacol. profile and the non-imidazole structure of III make it a promising tool compound in H3R research.
Journal of Medicinal Chemistry published new progress about Amnesia. 73576-33-7 belongs to class pyrimidines, name is 4-Chloro-6-isopropylpyrimidin-2-amine, and the molecular formula is C7H10ClN3, Product Details of C7H10ClN3.
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia